Beam Therapeutics (BEAM) Total Current Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Total Current Liabilities data on file, last reported at $74.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $74.6 million, down 47.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.6 million (down 47.32% YoY), and the FY2025 annual result was $96.9 million, down 46.76% from the prior year.
• Total Current Liabilities fell to $74.6 million in Q1 2026 per BEAM's latest filing, from $96.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $238.9 million in Q3 2022 and troughed at $74.6 million in Q1 2026.
• A 5-year average of $184.2 million and a median of $187.2 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 135.58% in 2022, then plunged 47.32% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $223.6 million in 2022, then fell by 8.06% to $205.6 million in 2023, then declined by 11.43% to $182.1 million in 2024, then tumbled by 46.76% to $96.9 million in 2025, then declined by 23.08% to $74.6 million in 2026.
• Business Quant data shows BEAM's Total Current Liabilities at $74.6 million in Q1 2026, $96.9 million in Q4 2025, and $182.6 million in Q3 2025.